top of page

Breaking The Vicious Cycle


We are developing a novel minimally invasive therapeutic device that provides adaptive treatment for NYHA stage 3 Heart Failure eliminating lung congestion.


Preventing cardiac decompensation, using a closed loop device that shifts fluids from the lung, reduces dyspnea and the cardiac workload

Our vision

Our Team

Extensive R&D leadership positions with 12+ years of medical device experience. Recently spearheaded the R&D of an OEM tissue oximeter device at Casmed (CT, USA) that led to the acquisition of the company by Edwards Lifesciences for over $100M

Professor and former dean of the biomedical engineering faculty at the Technion and former president of the International Society for Heart Research Israel group. Prof. Landesberg holds a Phd. In biomedical engineering and an M.D. Cum-Laude both from the Technion

Dr. Eckhouse is the founder and chairman of Alon MedTech ventures, a major player in the Israeli medical eco system, founded and invested in 20+ companies. such as Syneron Medical (acquired for $400M) and Ventor technologies (acquired for $325M)

Prof. Offer Amir, MD, FACC, FESC

Professor of Cardiology, Faculty of Medicine, Hebrew University, Jerusalem.

Director Heart Institute, Hadassah Medical ,Center, Jerusalem, Israel

President, Israel Heart Society 

Board Member, Heart Failure Association of the European Society of Cardiology


Hakidma 28,  Yokneam Illit


Thanks for submitting!

bottom of page